Krystal Biotech announces initial clinical results from KYANITE-1 study

Krystal Biotech (KRYS) announced initial clinical results from its ongoing KYANITE-1 study evaluating inhaled KB707 in patients with solid tumors of the lung. KB707 administered via inhalation demonstrated early evidence of monotherapy activity that was most pronounced in patients with advanced non-small cell lung cancer, NSCLC, where an objective response rate, ORR, of 27% and disease control rate of 73% were observed as of data cut-off on December 6, 2024. Monotherapy activity with inhaled KB707 provides further evidence of successful repeat administration of HSV-1 based inhaled lung gene delivery and builds on recent clinical data update for CF and AAT deficiency respiratory disease programs .